Alert Number 104
Date: June 24, 2024
In an article we published 2 days ago I said I was going to look into this Hsp90 inhibition business (using an antibiotic called 17-AAG) that might turn out to be a good for us. Well, here is the hot-off-the-presses scoop on the subject. We have just published (see 17AAG Clinical Trial) our review of a brand new-yet-to-be-published article in Blood by a couple of our favorite researchers, Dr. Kipps and Dr. Castro of UCSD, as well as a very interesting multi-center clinical trial using this drug for poor prognosis / late stage CLL patients. The trial is recruiting volunteers even as you read this article. I have a hunch this might be an interesting one. I like the science and the design of this clinical trial. If you are pondering therapy choices, this is one you should check out for yourself.
How is that for service — fast enough for you?
Be well,
Chaya
____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———